Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 3.2%

Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) traded up 3.2% during trading on Monday . The company traded as high as $3.54 and last traded at $3.54. 256,519 shares were traded during trading, a decline of 29% from the average session volume of 361,916 shares. The stock had previously closed at $3.43.

Atea Pharmaceuticals Stock Up 0.8 %

The company has a market cap of $325.93 million, a PE ratio of -1.97 and a beta of 0.18. The firm’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $3.77.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). On average, analysts predict that Atea Pharmaceuticals, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Bruce Polsky sold 17,544 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $3.49, for a total value of $61,228.56. Following the sale, the director now owns 65,606 shares of the company’s stock, valued at $228,964.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 17.80% of the company’s stock.

Hedge Funds Weigh In On Atea Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Atea Pharmaceuticals by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 16,179 shares of the company’s stock valued at $65,000 after buying an additional 6,526 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Atea Pharmaceuticals by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 42,521 shares of the company’s stock valued at $130,000 after buying an additional 8,024 shares during the last quarter. Sunpointe LLC acquired a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at approximately $36,000. Price T Rowe Associates Inc. MD raised its position in shares of Atea Pharmaceuticals by 21.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 67,137 shares of the company’s stock valued at $272,000 after buying an additional 11,968 shares during the last quarter. Finally, RPO LLC acquired a new position in shares of Atea Pharmaceuticals in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 86.67% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.